The Simply Good Foods Lawsuit Deadline Is Mostly Marketing. The Write-Down Is the Story.

Every time a stock falls hard, a dozen law firms post nearly identical press releases inviting burned shareholders to "contact us," because a court deadline is approaching and somebody needs to be named lead plaintiff. The reminder in front of you — Levi & Korsinsky, deadline October 13, 2026, ticker SMPL — is one of those. It's real, and it's also mostly a marketing function. The substantive thing hiding behind the boilerplate is more interesting than the date.

The company is The Simply Good Foods Company, the maker of Atkins and Quest nutrition snacks. In June 2024 it paid $280 million in cash for OWYN, the plant-based, allergen-free ready-to-drink protein shake brand (the name is just "Only What You Need"), betting on fast growth in a trendy category. Within roughly two years the company had written off about $200 million of that purchase price and the stock had fallen from above $40 to below $11 — a decline of more than 70%. The stock trades around $10 now.

Here is the strange part the lawsuit is organized around. The complaint alleges that a lot of the damage traces to a decision about where OWYN's pea protein would come from — in the plaintiffs' telling, a switch to an inferior supplier that degraded the product's taste, texture, and shelf life as it aged — combined with a loss of key management talent and a quietly bloating corporate cost structure. The allegations (and they are allegations) are that the company kept describing the integration as progressing as planned while these things were happening underneath.

Two disclosure days did the damage. On October 23, 2025, the company admitted OWYN sales had contracted nearly 17% year over year and that a pea protein sourcing decision had caused quality problems — while management said "the product issue is largely behind us."The stock fell about 17% in a day. Then in early April 2026, when it reported results, the company recorded a $187 million impairment against OWYN's intangible assets — cutting toward a cumulative ~$200 million write-down on a brand bought for $280 million — and slashed its fiscal 2026 net sales guidance to negative 7% to negative 10%. The stock fell another 27%.

First, what this deadline actually is, because that's the part most of the reminders get wrong. In a securities class action, the court picks one lead plaintiff — in practice, the shareholder with the largest verifiable loss — who then effectively runs the case. The rest of the class is in automatically: if you bought SMPL between October 24, 2024 and April 8, 2026, you're a class member even if you fill in nothing. The October 13 date is about who gets to be the named lead, not about whether you're covered. For the typical retail holder it's a reason lawyers are emailing you, not something you have to do to recover.

Now the part that matters for the investment case, which is the write-down itself. The $187 million charge against OWYN's intangibles was non-cash — no money left the building. What it actually does is an accounting admission: the expected future sales management paid for didn't materialize, so the balance sheet was marked down to match. Non-cash, but a genuine economic confession that the deal didn't deliver what the deal was supposed to deliver. It's not the only one. By its third fiscal quarter the company had booked a total $331 million of impairments across both OWYN and its flagship Atkins brand — evidence that the problems aren't isolated to the acquisition.

And the operating picture hasn't been clawing any of it back. The company now guides fiscal 2026 net sales to roughly $1.345–1.355 billion, down 6% to 7%, with gross margin expected to fall about 375 basis points and adjusted EBITDA down 19% to 21%. In the quarter ended May 30, 2026, net sales fell 6.3% and adjusted EBITDA fell 22.5%; Atkins sales were down 24.6%; Quest was roughly flat; OWYN grew in the quarter but is down year to date on soft velocity. To keep going it borrowed an extra $150 million in late 2025 — its term loan now stands at $400 million — with net debt at about 1.2 times adjusted EBITDA.

So the litigation is a symptom, not the disease. Whether the company's statements crossed from optimism into securities fraud is a legal question a judge will sort out, and class-action recoveries often end up modest relative to the damage done. But the economically material part is already public and already sitting in the ~$10 stock price: the acquisition lost most of its value, the flagship brand is shrinking, margins and cash earnings are falling, and the company levered up along the way. The useful question isn't whether you can "contact Levi & Korsinsky" in time. It's whether a declining foods company carrying a broken, written-down deal on its books is a business you'd want at this price in the first place.